Recombination Therapeutics, LLC

Recombination Therapeutics, LLC, based in Philadelphia, PA, is a precision oncology company dedicated to eliminating cancer by targeting DNA Damage Response (DDR) factors to combat drug resistance in genetically defined patient populations. Their innovative approach focuses on DNA polymerase Theta (Polq), a crucial repair factor that is essential for the survival of homologous recombination-deficient cancer cells while being dispensable for normal cells, making it an ideal therapeutic target.

The company is currently advancing its drug candidate targeting Polq in vivo and is also developing a first-in-class small-molecule inhibitor aimed at overcoming resistance to PARP inhibitors in both homologous recombination-deficient and proficient cancer cells. With a team of experienced professionals, Recombination Therapeutics is poised to make significant contributions to the field of precision oncology.

Generated from the website